The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | Thoughts on the RAMES study in mesothelioma
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, reviews data from the Phase II RAMES study (NCT03560973) which evaluated the addition of ramucirumab, a VEGFR2 inhibitor, to gemcitabine in patients with relapsed, advanced mesothelioma. He also discusses the next steps for this regimen in light of the impending CheckMate 743 data (NCT02899299). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology),
